American molecular diagnostic company GenMark Diagnostics has launched Plex Respiratory Pathogen 2 (RP2) Panel for commercial distribution and clinical use in the US.
The ePlex RP2 Panel is designed to identify 21 pathogens, including SARS-CoV-2 virus, which causes Covid-19 infection.
In addition to SARS-CoV-2, the test detects a range of respiratory pathogens such as influenza, adenovirus, rhinovirus and respiratory syncytial virus (RSV).
Combining the SARS-CoV-2 assay with the existing ePlex RP Panel is aimed at streamlining the diagnostic process for hospitals.
It will enable hospitals to check for multiple pathogens with a single test, saving time and resources, the company noted.
Furthermore, it is expected to help GenMark scale up its manufacturing efficiency and increase the number of its respiratory panels.
Earlier this month, the company submitted an emergency use authorisation (EUA) to the US Food and Drug Administration (FDA) for the ePlex Respiratory Pathogen 2 (RP2) Panel.
GenMark president and CEO Scott Mendel said: “The ePlex RP2 Panel is designed to enable clinicians to quickly determine the cause of infection and the best course of treatment.
“This is especially vital for individuals who are vulnerable, such as the elderly, people with compromised immune systems and children, and therefore at increased risk for the new coronavirus and other common and often serious respiratory illnesses.”
The ePlex RP2 Panel uses the company’s ePlex system. It has been cleared by the FDA for use with the ePlex Respiratory Pathogen (RP) Panel and Blood Culture Identification (BCID) Panels (Gram-positive, Gram-negative and Fungal pathogens).
In March, the FDA granted EUA to GenMark for its ePlex SARS-CoV-2 Test.